1. [Preoperative Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma].
- Author
-
Kawai T, Kochi M, Fujii M, Song K, Hagiwara K, Tamegai H, Watanabe M, Matsuno Y, Takayama Y, Suda H, and Takayama T
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell diagnosis, Cisplatin administration & dosage, Esophageal Neoplasms diagnosis, Esophageal Squamous Cell Carcinoma, Esophagectomy, Female, Fluorouracil administration & dosage, Humans, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell therapy, Chemoradiotherapy, Esophageal Neoplasms therapy
- Abstract
Background: The goal of this retrospective study was to investigate the efficacy and safety of preoperative chemoradiotherapy( NACR)in patients with Stage II or Stage III esophageal squamous cell carcinoma(SCC)., Methods: Between 2004 and 2014, a total of 86 patients underwent surgical resection in conjunction with NACR for esophageal SCC at our institute. Thirty-one patients(36.0%)had Stage II disease and 55 patients(64.0%)had Stage III disease., Results: The median age was 64(43-81)years. A total of 78 patients received the full NACR regimen. The most common major Grade 3 hematologic toxic effects of NACR were leukopenia and neutropenia(48 cases), while the most common major Grade 3 non-hematologic toxic effect was anorexia(12 cases). One patient died in the hospital and no patients died within 30 days after surgery. A pathological complete response was achieved in 23 cases. Pathological staging(number of cases)was Stage 0(23), Stage I (8), Stage II (28), Stage III (25), and Stage IV (2). The 5-year overall survival rate(OS)was 51.0%, and was 83.2% in Stage II patients and 29.9% in Stage III patients., Conclusion: Preoperative NACR is safe and may improve OS and downstaging rates in patients with esophageal SCC.
- Published
- 2016